Skip to main content

Advertisement

SpringerLink
Log in

Abnormal serum alanine aminotransferase levels are associated with impaired insulin sensitivity in young women with polycystic ovary syndrome

  • Original Articles
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Background and aim: Non-alcoholic fatty liver disease (NAFLD) and polycystic ovary syndrome (PCOS) are both associated with insulin resistance. We assessed whether NAFLD is associated with impaired insulin sensitivity in PCOS women independently of age and total adiposity. Subjects and methods: We enrolled 14 young PCOS women with NAFLD, 14 women with PCOS alone and 14 healthy controls, who were matched for age, body mass index, and total body fat (by bio-impedance analyzer). NAFLD was diagnosed by the surrogate measure of abnormal serum alanine aminotransferase (ALT) concentrations (defined as ALT>19 U/l) after excluding other secondary causes of liver disease (alcohol, virus, and medications). Insulin sensitivity was measured by euglycemic hyperinsulinemic clamp. Results: Insulin sensitivity was markedly decreased (p<0.001) in PCOS women with abnormal ALT levels, whereas it was similar between PCOS women with normal ALT levels and matched healthy controls (8.3±2.5 vs 12.1 ±1.7 vs 13.2±1.8 mg/min × kg of fat-free mass, respectively). PCOS women with abnormal ALT levels also had higher plasma triglycerides and lower HDL-cholesterol concentrations than those with PCOS alone. There was a strong inverse association between serum ALT levels and insulin sensitivity in the whole group of PCOS women (r=−0.59, p=0.0013). Conclusions: Abnormal serum ALT levels, as surrogate measure of NAFLD, are closely associated with impaired insulin sensitivity in young PCOS women in a manner that is independent from the contribution of age and total adiposity. Early recognition of NAFLD by radiological imaging tests in this group of young patients is warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999, 84: 4006–11.

    Article  PubMed  CAS  Google Scholar 

  2. Asunción M, Calvo RM, San Millán JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000, 85: 2434–8.

    PubMed  Google Scholar 

  3. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004, 89: 2745–9.

    Article  PubMed  CAS  Google Scholar 

  4. Dunaif A, Segal KR, Shelley DR, Green G, Dobrjansky A, Licholai T. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes 1992, 41: 1257–66.

    Article  PubMed  CAS  Google Scholar 

  5. Legro RS, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998, 83: 2694–8.

    PubMed  CAS  Google Scholar 

  6. DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril 2005, 83: 1454–60.

    Article  CAS  Google Scholar 

  7. de Alwis NM, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol 2008, 48 (Suppl 1): S104–12.

    Article  PubMed  CAS  Google Scholar 

  8. Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006, 40 (Suppl 1): S5–10.

    PubMed  Google Scholar 

  9. Kotronen A, Yki-Järvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008, 28: 27–38.

    Article  PubMed  CAS  Google Scholar 

  10. Schwimmer JB, Khorram O, Chiu V, Schwimmer WB. Abnormal aminotransferase activity in women with polycystic ovary syndrome. Fertil Steril 2005, 83: 494–7.

    Article  PubMed  CAS  Google Scholar 

  11. Setji TL, Holland ND, Sanders LL, Pereira KC, Diehl AM, Brown AJ. Nonalcoholic steatohepatitis and nonalcoholic fatty liver disease in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006, 91: 1741–7.

    Article  PubMed  CAS  Google Scholar 

  12. Cerda C, Pérez-Ayuso RM, Riquelme A, et al. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. J Hepatol 2007, 47: 412–7.

    Article  PubMed  CAS  Google Scholar 

  13. Gambarin-Gelwan M, Kinkhabwala SV, Schiano TD, Bodian C, Yeh HC, Futterweit W. Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Clin Gastroenterol Hepatol 2007, 5: 496–501.

    Article  PubMed  Google Scholar 

  14. Radziuk J. Insulin sensitivity and its measurement: structural commonalities among the methods. J Clin Endocrinol Metab 2000, 85: 4426–33.

    PubMed  CAS  Google Scholar 

  15. Moghetti P, Castello R, Negri C, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000, 85: 139–46.

    PubMed  CAS  Google Scholar 

  16. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004, 81: 19–25.

    Google Scholar 

  17. Azziz R, Carmina E, Dewailly D, et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006, 91: 4237–45.

    Article  PubMed  CAS  Google Scholar 

  18. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002, 137: 1–10.

    Article  PubMed  CAS  Google Scholar 

  19. Moghetti P, Tosi F, Castello R, et al. The insulin resistance in women with hyperandrogenism is partially reversed by anti-androgen treatment: evidence that androgens impair insulin action in women. J Clin Endocrinol Metab 1996, 81: 952–60.

    PubMed  CAS  Google Scholar 

  20. Pasquali R, Patton L, Pocognoli P, Cognigni GE, Gambineri A. 17-hydroxyprogesterone responses to gonadotropin-releasing hormone disclose distinct phenotypes of functional ovarian hyperandrogenism and polycystic ovary syndrome. J Clin Endocrinol Metab 2007, 92: 4208–17.

    Article  PubMed  CAS  Google Scholar 

  21. Moghetti P, Castello R, Negri C, et al. Insulin infusion amplifies 17 alpha-hydroxycorticosteroid intermediates response to adreno-corticotropin in hyperandrogenic women: apparent relative impairment of 17,20-lyase activity. J Clin Endocrinol Metab 1996, 81: 881–6.

    PubMed  CAS  Google Scholar 

  22. Zanolin ME, Tosi F, Zoppini G, et al. Clustering of cardiovascular risk factors associated with the insulin resistance syndrome: assessment by principal component analysis in young hyperandrogenic women. Diabetes Care 2006, 29: 372–8.

    Article  PubMed  Google Scholar 

  23. Korenblat KM, Fabbrini E, Mohammed BS, Klein S. Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology 2008, 134: 1369–75.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  24. Schindhelm RK, Diamant M, Dekker JM, Tushuizen ME, Teerlink T, Heine RJ. Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes Metab Res Rev 2006, 22: 437–43.

    Article  PubMed  CAS  Google Scholar 

  25. Day CP. From fat to inflammation. Gastroenterology 2006, 130: 207–10.

    Article  PubMed  CAS  Google Scholar 

  26. Targher G, Bertolini L, Rodella S, et al. NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. Obesity (Silver Spring) 2008, 16: 1394–9.

    Article  CAS  Google Scholar 

  27. Jarrar MH, Baranova A, Collantes R, et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008, 27: 412–21.

    Article  PubMed  CAS  Google Scholar 

  28. Targher G, Arcaro G. Nonalcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 2007, 191: 235–40.

    Article  PubMed  CAS  Google Scholar 

  29. Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006, 44: 865–73.

    Article  PubMed  CAS  Google Scholar 

  30. Targher G, Bertolini L, Poli F, et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 2005, 54: 3541–6.

    Article  PubMed  CAS  Google Scholar 

  31. Targher G, Bertolini L, Rodella S, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 2007, 30: 2119–21.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Endocrinology, Department of Biomedical and Surgical Sciences, University of Verona, Verona, Italy

    G. Targher MD, E. Solagna, F. Tosi, R. Castello, G. Spiazzi, G. Zoppini, M. Muggeo & P. Moghetti

  2. Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, England

    C. P. Day

Authors
  1. G. Targher MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Solagna
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Tosi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. Castello
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G. Spiazzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. Zoppini
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. Muggeo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. C. P. Day
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. P. Moghetti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. Targher MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Targher, G., Solagna, E., Tosi, F. et al. Abnormal serum alanine aminotransferase levels are associated with impaired insulin sensitivity in young women with polycystic ovary syndrome. J Endocrinol Invest 32, 695–700 (2009). https://doi.org/10.1007/BF03345743

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03345743

Keywords

Search

Navigation